论文部分内容阅读
目的探讨人绝经期促性腺素(HMG)治疗多囊卵巢综合征性不孕的临床疗效。方法选取2012年6月—2015年6月漳州市妇幼保健院收治的多囊卵巢综合征性不孕患者120例,随机分为氯米芬组和氯米芬+HMG组,各60例。氯米芬组给予氯米芬促排卵治疗,氯米芬+HMG组在氯米芬组基础上加用HMG治疗,并改善胰岛素抵抗,降低雄激素水平。观察指标:(1)周期排卵率、妊娠率;(2)治疗前和治疗后患者卵泡刺激素(FSH)水平、睾酮水平、促黄体激素水平的差异。结果氯米芬+HMG组周期排卵率、妊娠率高于氯米芬组,差异有统计学意义(P<0.05)。治疗前两组患者FSH、睾酮、促黄体激素水平比较,差异无统计学意义(P>0.05);治疗后氯米芬+HMG组FSH、睾酮水平高于氯米芬组,促黄体激素水平低于氯米芬组,差异有统计学意义(P<0.05)。结论 HMG治疗多囊卵巢综合征性不孕的临床疗效确切,可有效改善患者激素水平,促进排卵,增加妊娠率。
Objective To investigate the clinical efficacy of human menopausal gonadotropin (HMG) in the treatment of infertility with polycystic ovary syndrome. Methods 120 patients with polycystic ovary syndrome infertility admitted to Zhangzhou MCH from June 2012 to June 2015 were randomly divided into clomiphene citrate group and clomiphene citrate group, 60 cases in each group. The clomiphene citrate group was given clomiphene for ovulation induction. Clomiphene + HMG group was treated with HMG on the basis of clomiphene citrate group, and insulin resistance was improved and the level of androgen was decreased. Observed indicators: (1) ovulation rate, pregnancy rate; (2) before treatment and after treatment follicle stimulating hormone (FSH) levels, testosterone levels, luteinizing hormone levels differences. Results The rates of ovulation and pregnancy in clomiphene + HMG group were significantly higher than those in clomiphene citrate group (P <0.05). FSH, testosterone and luteinizing hormone in the two groups before treatment had no significant difference (P> 0.05). After treatment, the levels of FSH and testosterone in clomiphene + HMG group were higher than those in clomiphene group, and the levels of luteinizing hormone In clomiphene citrate group, the difference was statistically significant (P <0.05). Conclusion HMG treatment of polycystic ovary syndrome infertility clinically effective, can effectively improve the patient’s hormone levels, promote ovulation and increase pregnancy rate.